UK Histiocytosis Advisory Panel HLH Adult and Adolescent (For clinicians use only).

Referring a patient

    1. Complete the brief form below. Please do not send multiple separate documents per patient.
    2. A UKHAP number may be provided in the response/outcome. Please insert the UKHAP number if the patient has been previously discussed.
    3. Submit the completed form.
    4. Record in the patient’s medical record that they or their parent/guardian agree to their case being discussed at the UK Histio Advisory Panel.
    5. The Advisory Panel operates on the basis that its members are part of the Care Team of the patients who are referred and therefore have legitimate access to patient identifiable information including name, date of birth and NHS number. 
UKHR – UK Histiocytosis Registry Invite the patient or their parent/guardian to participate in the UK Histiocytosis Registry (UKHR), tick if they agree and provide a contact email for the patient or their parent. Patients who wish to join will be consented remotely by telephone or e-consent by the study team. Alternatively, you may take consent yourself using PIS and consent forms found here: https://www.ukhr.org/consent/ If a HAP number has been issued, please use the HAP number (e.g. 0001) as the Study Number (e.g. UKHR-HAP-0001) on the consent form and email completed forms to sarah.pagan@nhs.net Please do not copy or send the form below to this email address It is only for UKHR use. UKHR is approved for England and Wales REC 18/NE/0374; IRAS 238319. For national and EU service evaluation and audit it is legitimate for the Advisory Panel to provide de-identified information (removal of name, date of birth and NHS number) without specific patient consent. For national, EU and international research, transfer of anonymised information will require consent to join the UKHR which is REC-approved for this purpose.

    UK HISTIOCYTOSIS ADVISORY PANEL HLH ADULT & ADOLESCENT (for Clinicians Use Only)



    * HAP number will be provided.  Please insert if previously discussed.
      


    Your support is vital to ensure that we can continue to deliver our Research and Information Programmes. Thank you.